EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Empowering brain tumor management: chimeric antigen receptor macrophage therapy

Fan Feng, Jianyu Shen, Qichao Qi, Yulin Zhang, Shilei Ni

Theranostics · 2024 · 14 (14) · 5725-5742

DOI: 10.7150/thno.98290 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Theranostics, 2024. Verfasst von Fan Feng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Qilu Hospital and Institute of Brain and Brain-Inspired Science, Cheeloo College of Medicine, Shandong University, 107 We…. Hauptthemen laut MEDLINE: Brain Neoplasms, Receptors, Chimeric Antigen, Tumor Microenvironment, Immunotherapy, Adoptive. Die Arbeit wurde bisher 24-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brain tumors pose formidable challenges in oncology due to the intricate biology and the scarcity of effective treatment modalities. The emergence of immunotherapy has opened new avenues for innovative therapeutic strategies. Chimeric antigen receptor, originally investigated in T cell-based therapy, has now expanded to encompass macrophages, presenting a compelling avenue for augmenting anti-tumor immune surveillance. This emerging frontier holds promise for advancing the repertoire of therapeutic options against brain tumors, offering potential breakthroughs in combating the formidable malignancies of the central nervous system. Tumor-associated macrophages constitute a substantial portion, ranging from 30% to 50%, of the tumor tissue and exhibit tumor-promoting phenotypes within the immune-compromised microenvironment. Constructing CAR-macrophages can effectively repolarize M2-type macrophages towards an M1-type phenotype, thereby eliciting potent anti-tumor effects. CAR-macrophages can recruit T cells to the brain tumor site, thereby orchestrating a remodeling of the immune niche to effectively inhibit tumor growth. In this review, we explore the potential limitations as well as strategies for optimizing CAR-M therapy, offering insights into the future direction of this innovative therapeutic approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsReceptors, Chimeric AntigenTumor MicroenvironmentImmunotherapy, AdoptiveMacrophagesHumansAnimalsTumor-Associated MacrophagesT-LymphocytesImmunotherapy

Stichwörter der Autor:innen

Brain tumorChimeric antigen receptorImmunotherapyMacrophage

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Neurosurgery, Qilu Hospital and Institute of Brain and Brain-Inspired Science, Cheeloo College of Medicine, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China.

Zitieren

APA

Feng, F., Shen, J., Qi, Q., Zhang, Y., & Ni, S. (2024). Empowering brain tumor management: chimeric antigen receptor macrophage therapy. Theranostics, 14(14), 5725-5742. https://doi.org/10.7150/thno.98290

Vancouver

Feng F, Shen J, Qi Q, Zhang Y, Ni S. Empowering brain tumor management: chimeric antigen receptor macrophage therapy. Theranostics. 2024;14(14):5725-5742. doi:10.7150/thno.98290

BibTeX
@article{Feng2024,
  author = {Feng, Fan and Shen, Jianyu and Qi, Qichao and Zhang, Yulin and Ni, Shilei},
  title = {Empowering brain tumor management: chimeric antigen receptor macrophage therapy},
  journal = {Theranostics},
  year = {2024},
  volume = {14},
  number = {14},
  pages = {5725--5742},
  doi = {10.7150/thno.98290}
}
Kostenlos starten →